Referencias
1. Lacković Z. Botulinum Toxin and Pain. Handb Exp Pharmacol. 2021;263:251-64.
2. Ficha técnica Toxina Botulínica [Internet]. Agencia Española de Medicamentos y Productos Sanitarios; 2022. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/63194/FT_63194.pdf
3. Matak I, Bölcskei K, Bach-Rojecky L, Helyes Z. Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins (Basel). 2019;11:459.
4. Peng Chen Z, Morris JG Jr, Rodriguez RL, Wagle Shukla A, Tapia-Núñez J, Okun MS. Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel). 2012;4(11):1196-222.
5. Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101(3):366-70.
6. Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174():977-82.
7. Drinovac V, Bach-Rojecky L, Matak I, Lacković Z. Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology. 2013;70:331-7.
8. Bach-Rojecky L, Lacković Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav. 2009;94(2):234-8.
9. Sepulcre Agulló R, Gálvez Mateos R, Pozuelo Calvo R. Uso de toxina botulínica en dolor tras amputación. Rev Soc Esp Dolor. 2021;28(6):334-44. DOI: 10.20986/resed.2022.3943/2021.
10. Safarpour Y, Jabbari B. Botulinum toxin treatment of pain syndromes -an evidence based review. Toxicon. 2018;147:120-8.